- Home
- SOWG vs BRTX Comparison
SOWG vs BRTX Comparison
Compare SOWG & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOWG | BRTX |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Managed Health Care |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 9.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOWG | BRTX |
|---|---|---|
| Price | $0.52 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 75.2K | 35.5K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,270,357.00 | $383,400.00 |
| Revenue This Year | $6.81 | $112.14 |
| Revenue Next Year | N/A | $139.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.70 |
| 52 Week Low | $0.47 | $0.98 |
| 52 Week High | $4.12 | $2.55 |
Technical Indicators
Market Signals| Indicator | SOWG | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 47.23 |
| Support Level | $0.47 | $1.04 |
| Resistance Level | $0.55 | $1.23 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 20.85 | 65.26 |
Price Performance
Historical ComparisonAbout SOWG Sow Good Inc.
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.